Targeting Myeloid CD36 to Enhance Macrophage-Mediated Immunity: A Novel Strategy Against Hepatic Fibrosis
Myeloid cell CD36 deficiency reduces hepatic fibrosis by preventing macrophage ferroptosis and restoring antigen presentation, thereby enhancing CD8+ T cell-mediated adaptive immunity. This identifies CD36 as a promising therapeutic target in liver fibrosis management.